Insights into brain metastasis in patients with + lung cancer: is the brain truly a sanctuary? by unknown
CLINICAL
Insights into brain metastasis in patients with ALK+ lung cancer:
is the brain truly a sanctuary?
Gouji Toyokawa1 & Takashi Seto1 & Mitsuhiro Takenoyama1 & Yukito Ichinose1
Published online: 5 September 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Anaplastic lymphoma kinase (ALK) has been iden-
tified to exert a potent transforming activity through its rear-
rangement in non-small cell lung cancer (NSCLC), and pa-
tients (pts) with ALK rearrangement can be treated more suc-
cessfully with ALK inhibitors, such as crizotinib, alectinib,
and ceritinib, than with chemotherapy. Despite the excellent
efficacy of ALK inhibitors, resistance to these drugs is inevi-
tably encountered in most ALK-rearranged pts. Cases of resis-
tance are subtyped into three groups, i.e., systemic, oligo, and
central nervous system (CNS) types, with the CNS being used
to be considered a sanctuary. With regard to the management
of CNS lesions in pts with ALK+ NSCLC, a growing body of
evidence has gradually demonstrated the intracranial (IC) ef-
ficacy of ALK inhibitor (ALKi) in ALK+ NSCLC pts with
brain metastases (BMs). Although the efficacy of crizotinib
for the CNS lesions remains controversial, a recent retrospec-
tive investigation of ALK+ pts with BM enrolled in PROFILE
1005 and PROFILE 1007 demonstrated that crizotinib is as-
sociated with a high disease control rate for BM. However,
BM comprises the most common site of progressive disease in
pts with or without baseline BMs, which is a serious problem
for crizotinib. Furthermore, alectinib can be used to achieve
strong and long-lasting inhibitory effects on BM. In addition
to alectinib, the IC efficacy of other next-generation ALK
inhibitors, such as ceritinib, AP26113 and PF-06463922, has
been demonstrated. In this article, we review the latest evi-
dence regarding the BM and IC efficacy of ALK inhibitors in
pts with ALK+ NSCLC.
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1 Introduction
Rearrangement in the anaplastic lymphoma kinase (ALK)
gene is one of the potent oncogenic drivers in patients (pts)
with non-small cell lung cancer (NSCLC) and occurs in ap-
proximately 5 % of cases [1, 2]. Tyrosine kinase inhibitors
(TKIs) against ALK, such as crizotinib, alectinib, and
ceritinib, have recently been developed and shown to exert a
potent antitumor activity in pts with ALK-rearranged NSCLC
[3–9]. With regard to crizotinib, which has been originally
developed as a c-Met inhibitor, the response rate (RR) and
progression-free survival (PFS) of crizotinib in first- and
second-line settings for advanced ALK+ NSCLC are 74 and
65 % and 10.9 and 7.7 months, respectively, which are signif-
icantly better than those achieved with standard chemotherapy
[5, 6]. Alectinib, a next-generation ALK inhibitor (ALKi), is
also known to exhibit a high antitumor activity for pts with
ALK+ NSCLC, i.e., RR and PFS of 93.5 % and 27.7 months,
respectively [7]. Critically, alectinib is effective for ALK+
NSCLC pts with a history of prior crizotinib treatment [8]
and ceritinib has been shown to demonstrate high efficacy
for pts with ALK+ NSCLC treated with or without prior ther-
apy with crizotinib [9].
Metastasis to the central nervous system (CNS) is a diffi-
cult concern to be resolved in many types of cancer as a result
of inadequate penetration of antitumor agents, difficult acces-
sibility, and neurological symptoms leading to a decreased
performance status, and lung cancer is the leading cancer to
metastasize to the brain. According to the SEER database,
lung cancer occurred in 19.9 % of 16,210 pts, followed by
melanoma at 6.9 % [10, 11]. In pts with advanced NSCLC,
* Gouji Toyokawa
gouji104kawa@gmail.com
1 Department of Thoracic Oncology, National Kyushu Cancer Center,
3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan
Cancer Metastasis Rev (2015) 34:797–805
DOI 10.1007/s10555-015-9592-y
approximately 10–20 % of cases are considered to be accom-
panied by CNS metastases prior to first-line treatment [12,
13]. With regard to the incidence of brain metastasis (BM)
in pts with ALK+ NSCLC who are naïve to ALKi, several
retrospective studies have reported rates ranging from approx-
imately 20 to 30 %, which is comparable to that observed in
epidermal growth factor receptor (EGFR)-mutated NSCLC
pts [14, 15]. In large trials examining ALKi, the frequency
of BM in ALKi-naïve pts has been reported to range from
approximately 25 to 40 %, which is high in pts with a history
of chemotherapy [5–7, 16]. Furthermore, ALK-rearranged
NSCLC pts exhibiting a history of prior ALKi treatment are
reported to harbor a high incidence of CNS metastases, i.e.,
from approximately 45 to 70%, which suggests that BM is the
most common pattern of failure of ALKi [8, 9, 17–21]. There-
fore, it is crucial to properly treat CNS lesions as well as
systemic lesions.
With regard to the efficacy of ALKi for BM in ALK+
NSCLC pts, the efficacy of crizotinib was analyzed in retro-
spective analyses of the PROFILE 1005 and PROFILE 1007
trials [22]. The disease control rate (DCR) and RR in previ-
ously untreated and treated BM cases were 56 and 62 %, and
18 and 33 %, respectively. In addition, several reports have
indicated that alectinib exhibits excellent antitumor efficacy
for CNSmetastases inALK+NSCLC pts with or without prior
ALKi treatment, including crizotinib and ceritinib [7, 8, 19,
20, 23–25]. According to the results of AF-002JG, the intra-
cranial (IC) objective RR was intriguingly 52 %, with a com-
plete response rate of 29 % [8]. In concordance with the clin-
ical efficacy observed in ALK+ pts, the remarkable efficacy of
alectinib has been demonstrated in experimental models of IC
metastases [26, 27]. The high efficacy of alectinib for ALK+
CNS metastases is considered to be due to its high penetration
to the brain as well as poor efflux from the brain, owing to
experimental results demonstrating that alectinib might not be
transported by P-glycoprotein (P-gp) efflux protein, a key
protein for blood-brain barrier (BBB) penetration [26]. In ad-
dition to alectinib, ceritinib has been shown to be effective for
BM, and novel compounds, such as AP26113 and PF-
06463922, have also been demonstrated to be effective for
CNS lesions [16–18, 21, 28].
Therefore, a growing body of evidence has been accumu-
lated for BM in pts with ALK+ NSCLC. In this review article,
we review up-to-date evidence on recent clinical and basic
results regarding BM and discuss the optimal management
of BM in pts with ALK-positive NSCLC.
2 Incidence of IC metastases in pts with ALK+
NSCLC
The brain is a devastating metastatic site of malignancies,
including lung cancer, as metastasis to the brain might result
in neurological dysfunction and cognitive impairment, which
can lead to an impaired quality of life. The presence of IC
metastases is known to be associated with a poor prognosis.
According to the report by Paul and colleagues, the median
survival time of pts with BM is 7.0 months from the start of
treatment of BM and, in particular, pts at high risk, as defined
based on various determinants, including the number of BM
lesions, achieve a survival as short as 3.0 months [29].
ALK is normally expressed in the CNS, small intestine,
and testes and is considered to play a role in the development
of the nervous system; however, its involvement in IC metas-
tasis and its significance in normal organs have yet to be
elucidated [30]. With regard to the baseline frequency of
BM in pts with ALK+ NSCLC at the time of diagnosis of
the disease, two retrospective studies showed a frequency of
approximately 25 %, which is comparable to that observed in
other subsets of NSCLC driven by EGFR and Kirsten rat
sarcoma viral oncogene homolog (KRAS) [14, 15]. This inci-
dence is consistent with that reported in the PROFILE 1014
trial, which compared crizotinib with chemotherapy in pts
with ALK-rearranged NSCLC as a first-line therapy; i.e., the
frequency of BM in both arms was 26 and 27 %, respectively
[6].
With regard to the incidence of CNS metastases in ALKi-
naïve ALK+ NSCLC pts previously treated with chemothera-
py, the PROFILE 1007 trial, which compared crizotinib with
pemetrexed or docetaxel as a second-line treatment in ALKi-
naïve NSCLC pts, showed that the prevalence of BM was
approximately 35 % in both arms, which is higher than that
observed in the first-line PROFILE 1014 study (Table 1) [5].
Similar to this incidence, a retrospective exploratory analysis
of the PROFILE 1015 and PROFILE 1007 trials showed that
275 (31 %) of the enrolled 888 ALK+ pts had BMwithout any
symptoms [22]. A phase II study (AF-001JP) that investigated
the efficacy of alectinib at a dose of 300 mg twice daily for
ALKi-naïve NSCLC pts who had received one or more lines
of chemotherapy showed almost the same prevalence (33 %)
of BM as that seen in the retrospective study of PROFILE
1005 and PROFILE 1007 [7]. In the ASCEND-3 study of
ceritinib in ALKi-naïve pts who had received one to three
prior antineoplastic regimens, the prevalence of CNS metas-
tasis was 40.3 % (50/124) [16].
With regard to the incidence of BM in pts with ALK rear-
rangement previously treated with ALKi, several prospective
studies have reported the detailed prevalence of BM in such
populations, which ranges from approximately 40 to 70 %, as
shown in Table 1 [8, 16–21, 28]. Almost all pts enrolled in
these studies had been treated with crizotinib, suggesting that
BM is very common in pts with crizotinib-treated ALK+
NSCLC. In fact, a retrospective study by Weickhardt et al.
showed that 13 (46 %) among 28 cases of disease progression
on crizotinib were identified to be due to BM [31]. Further-
more, a retrospective investigation of the PROFILE 1005 and
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PROFILE 1007 trials demonstrated that the CNSwas the most
frequently affected organ in cases of progressive disease (PD)
in pts on crizotinib with or without a previous history of treat-
ment for baseline BM, which ranged from 70 to 72 % [22]. In
addition, with regard to the cumulative risk of IC metastasis in
ALK+ NSCLC pts, Rangachari and colleagues reported that
the incidence of BM in ALK-rearranged pts at 1, 2, and 3 years
from the initial diagnosis was 23.8, 45.5, and 58.4 %, respec-
tively [15]. Therefore, IC metastases are more commonly ob-
served after the failure of antineoplastic agents including
ALKi, which is one of the most confusing issues to be ad-
dressed in the management of pts with ALK-rearranged
NSCLC.
3 Antitumor activity of ALKi against BM in pts
with ALK+ NSCLC
CNS metastasis is usually insensitive to chemotherapy, and
the RR of chemotherapy for BM from solid tumors has been
reported to be approximately 20 to 40 %, suggesting that the
brain is a sanctuary site in the treatment of pts with advanced
lung cancer [32]. With regard to the efficacy of targeted ther-
apy for BM arising from lung cancer, several studies have
reported that erlotinib, a representative targeted agent, might
be effective for CNS lesions. Erlotinib has been found to
achieve a longer survival time in EGFR-mutated pts with
BM compared with gefitinib, and the higher efficacy of erlo-
tinib versus gefitinib is assumed to be due to the higher con-
centration and penetration of erlotinib in the cerebrospinal
fluid (CSF) [33, 34]. In addition, the proportion of CNS PD
is higher in cases of gefitinib compared with erlotinib: gefitin-
ib versus erlotinib, approximately 35 % versus up to 10 %
[35–38]. Hence, the efficacy of molecular-targeted agents for
BM has gradually been clarified.
With regard to the efficacy of ALKi for CNS metastasis in
pts with ALK rearrangement-positive NSCLC, much evidence
was reported at the ASCO Annual Meeting in 2015 (Table 1),
and in this section, we review this evidence in detail. In order
to clarify the antitumor effect of each ALKi agent, the DCR
and RR for the target lesions are specified in Table 1.
3.1 Crizotinib
The PROFILE trials demonstrated that crizotinib, a first-in-
class ALKTKI, achieves a significantly higher response in the
systemic lesions of ALK+ NSCLC pts as compared with che-
motherapy; however, it was not fully clarified whether










Prior ALKi Target lesion Intracranial response (target lesion)
DCR RR
PROFILE 1007 [5] Crizotinib 173 60 (35) 2nd No Not described Not described
PEM or DOC 174 60 (34)
PROFILE 1014 [6] Crizotinib 172 45 (26) 1st No Not described 56 % at 24 weeks Not described
PEM+CBDCA
or CDDP




Crizotinib 888 275 (31) ≥2nd No 22 (previously
untreated)





AF-001JP [7] Alectinib 46 15 (33) ≥2nd No Not described Not described
AF-002JG [8] Alectinib 47 21 (45) ≥2nd Yes (crizotinib) 9 77.8 % 55.6 %
NP28673 [19] Alectinib 138 84 (61) ≥2nd Yes (crizotinib) 35 85.7 % 57.1 %
NP28761 [20] Alectinib 87 52 (60) ≥2nd Yes (crizotinib) 16 100 % 68.8 %
JP28927 [53] Alectinib 35 23 (65.7) ≥1st Yes (29/35, crizotinib
and other ALK
inhibitors)
2 100 % 100 %
ASCEND-1 [17] Ceritinib 246 124 (50.4) ≥1st Yes (98/124, other
ALK inhibitors)
29 58.6 % 34.5 %
ASCEND-2 [18] Ceritinib 140 100 (71.4) ≥2nd Yes (crizotinib) 33 84.8 % 39.4 %
ASCEND-3 [16] Ceritinib 124 50 (40.3) ≥2nd No 17 82.4 % 58.8 %
AP26113 [21] AP26113 79 52 (66) ≥1st Yes (71/79, crizotinib) 15 87 % 53 %
PF-06463922 [28] PF-06463922 44a 52 (66) ≥1st Yes (37/44, ALKi) 14 72 % 36 %
BM brain metastasis, No. number, pts patients, Tx therapy, DCR disease control rate, RR response rate, IC intracranial, DOR duration of response, PEM
pemetrexed, DOC docetaxel, CBDCA carboplatin, CDDP cisplatin
a Thirty-three (75 %) and 11 (25 %) were ALK+ and ROS1+ patients
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crizotinib is effective for CNS metastasis [3–6]. In the PRO-
FILE 1014 trial, the IC DCR at 24 weeks after the start of
treatment was reported and crizotinib and first-line standard
chemotherapy of platinum agents with pemetrexed achieved
rates of 56 and 25 %, respectively, with a statistically signifi-
cant difference (Table 1). A large retrospective study of the
PROFILE 1015 and PROFILE 1007 trials examined the effi-
cacy of crizotinib for BM in pts with ALK rearrangement with
or without a history of prior cranial radiotherapy [22]. Among
888 pts enrolled in these trials, 275 pts (31 %) were judged to
harbor asymptomatic BM and divided into cases previously
untreated or treated with radiotherapy (n=109 and 166, re-
spectively). The DCRs at 12 weeks in the previously untreated
or treated BM cases were 56% (95 % confidence interval (CI)
46–66) and 62 % (95 % CI 54–70), respectively, and the RRs
of crizotinib in the target lesion in BM cases previously un-
treated or treated with radiation were 18 % (95 % CI 5–40)
and 33 % (95 % CI 13–59), respectively. Although the differ-
ence in the RR observed between the two groups appears to be
significant, attention should be paid to interpreting this result
because radiotherapy for BM prior to enrollment in these stud-
ies might have affected the RR. The IC durations of response
(DORs) in previously treated or untreated pts with a con-
firmed objective response was 26.4 (95 % CI 6.1–59.3) and
not reached (95 % CI 6.0–59.9), respectively. Furthermore,
the studies showed that systemic PFS was not affected by
the presence or absence of BM at baseline. Intriguingly,
non-target or new lesions in the brain accounted for 71 % of
RECIST PD cases in pts with baseline BM and 25 % of PD
cases in pts without baseline BM, suggesting that the CNS
remained the dominant site of acquired resistance to crizotinib
in the pts with or without BM at baseline.
Furthermore, several case reports have reported the contra-
dictory efficacy of crizotinib for CNS lesions, including
intramedullary spinal cord metastasis and leptomeningeal car-
cinomatosis, in ALK+ NSCLC pts [39–45]. The rapid and
long-lasting response of BM to crizotinib was recently report-
ed by two groups [39, 40], and high-dose crizotinib has been
shown to temporarily control BM refractory to standard-dose
crizotinib [42]. In contrast, some reports have suggested that
BM is insensitive to crizotinib, which leads to the notion that
the brain is a sanctuary site or Achilles heel [43, 44]. Impor-
tantly, a report by Costa and colleagues examined the concen-
tration of crizotinib in the CSF of an ALK+ NSCLC pt who
had progressed on crizotinib for BM and was treated with
whole brain irradiation (WBI) and then resumed crizotinib
after WBI [43]. That report demonstrated that concentration
of crizotinib restarted after WBI in the CSF was as low as
0.616 ng/ml, while the plasma concentration of the agent
was 237 ng/ml, with a CSF-to-plasma ratio of 0.0026. This
result suggests that the possible poor BBB penetration of cri-
zotinib might explain the failure of crizotinib to be effective
for BM in cases of ALK+ NSCLC. Another report published
by Metro et al. also analyzed the CSF concentrations of crizo-
tinib in two pts with ALK rearrangement whose CNS lesions
were successfully treated with crizotinib [46]. In one case, in
which the pt was naïve to radiotherapy for CNS lesions and
experienced a complete CNS response, the concentrations of
crizotinib in the serum and CSF were 587 and 0.35 ng/ml,
respectively, with a CSF-to-serum ratio of 0.0006. In another
case, in which the pt progressed on crizotinib for BM and was
treated with WBI and subsequently continued crizotinib with
a temporary discontinuation during WBI, the concentrations
of crizotinib in the serum and CSF were 800 and 0.80 ng/ml,
respectively, with a CSF-to-serum ratio of 0.001. Intriguingly,
despite the poor CNS concentration of crizotinib, the CNS
lesions in these two pts were successfully tread with crizotin-
ib, suggesting the possible involvement of other factors in the
CNS accounting for the benefit of crizotinib. Based on these
findings, a low CSF-to-serum ratio alone does not explain the
insensitivity of crizotinib to BM, which should be clarified in
further investigations.
3.2 Alectinib
Alectinib/CH5424802 was developed to be highly selective
against ALK and later identified to block ret proto-oncogene
[47, 48]. Preclinical experiments have demonstrated that this
agent is capable of blocking mutated forms of ALK, including
a gatekeeper mutation of L1196M conferring crizotinib resis-
tance, as well as wild-type ALK [47, 49]. With regard to the
antitumor efficacy of alectinib for BM, intracranial tumor im-
plantation mouse models of ALK+ NSCLC cells have demon-
strated that alectinib potently induces IC tumor regression
compared with crizotinib, resulting in prolonged survival
[26, 27]. This potent antineoplastic activity of alectinib against
BM is assumed to be due to high rate of penetration of the
agent into the brain, and intriguingly, it has been suggested
that alectinib might not be transported by P-gp, which is
expressed in the BBB and plays a key role in BBB penetration
(Fig. 1) [26, 50]. In addition, data for five alectinib-treated pts






Fig. 1 Alectinib is not a substrate of P-gp, which is expressed in the BBB
and plays a key role in BBB penetration.BBB blood-brain barrier,P-gp P-
glycoprotein
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between the concentration of alectinib in the CSF and paired
systemic unbound alectinib [8].
The phase II portion of the AF-001JP trial included 33 %
pts with BM among 46 pts enrolled at baseline, although the
detailed responses have not yet been reported [7, 51]. Four
(33 %) of 12 pts who experienced PD showed CNS progres-
sion, and half of the pts with baseline IC metastasis continued
to be treated with alectinib without any PD at brain or system-
ic sites. The median PFS, which was not reached and was
estimated to reach beyond 29 months, was affected by the
presence of BM at baseline, i.e., 35.3 months versus not
reached in the pts with or without BM at baseline, respective-
ly. Furthermore, other studies investigating alectinib, such as
AF-002JG, NP2867, and NP28761, were recently designed to
evaluate crizotinib-resistant or intolerant pts with ALK trans-
location and showed detailed data regarding the efficacy of
alectinib for IC lesions [8, 19, 20]. In the AF-002JG study,
among 21 pts with BM at baseline, six (29 %), five (24 %),
eight (38 %), and two (10 %) achieved a complete response
(CR), partial response, stable disease, and PD, respectively
[8]. When limited to nine pts with measurable BM lesions,
the objective RR (ORR) and DCR were as high as 55.6 and
77.8 %, respectively. Intriguingly, one of two pts experiencing
IC PD, despite a systemic good response, had been treated
with stereotactic radiotherapy for BM, and only one lesion
was enlarged, with other lesions being decreased. Thereafter,
surgical resection was performed for the enlarging lesion,
which was confirmed to be necrotic, without any viable cancer
cells, suggesting pseudo-progression (PsP). In addition to this
report, Ou et al. reported two pts who experienced radiation
necrosis presenting as PsP when treated with alectinib for
previously irradiated BM [52]. These results underline the
importance of distinguishing truly progressive disease from
PsP when treating previously radiated IC lesions with
alectinib, although the optimal way to do this has yet to be
established, other than surgical resection.
The phase II NP28673 and NP28761 studies are aimed to
examine the efficacy and safety of alectinib at a dose of
600 mg twice daily for pts with ALK+ NSCLC who
progressed on or did not respond to crizotinib [19, 20]. In
the NP28783 trial, the frequency of BMwas 84 (61%) among
138 pts and 35 pts had measurable CNS lesions. The IC ORR
and DCR in pts with measurable BM were 57.1 % (95 % CI
39.4–73.7) and 85.7 % (95 % CI 69.7–95.2), respectively, and
the CR was observed in seven pts (20.0 %). In addition, the
DOR in the CNS was as long as 10.3 months (95 % CI 7.6–
11.2). Moreover, the RR in the pts treated with or without
prior radiation was 39.3 and 52.2 %, respectively, and consid-
ering the possibility of PsP, attention should be paid to
interpreting the slightly low RR values noted in pts previously
treated with radiation. The NP28761 trial also demonstrated
the excellent efficacy of alectinib for IC lesions: the RR and
DCR in the pts with measurable BM at baseline were 68.8 and
100 %, respectively. The antitumor activity of alectinib for
BM in cases of ALK+ NSCLC pre-treated with crizotinib
was also reported in the JP28927 study [53]. With regard to
the relapse pattern, nine out of 23 (65.7 %) pts with baseline
BMwere identified to progress on alectinib and all pts, except
one, progressed at sites other than the brain. Furthermore,
alectinib has been reported to be effective for CNS metastasis
associated with leptomeningeal involvement previously treat-
ed with crizotinib and alectinib [25]. Therefore, alectinib is
highly effective for CNS lesions in ALK+ NSCLC pts. Differ-
ence in systemic and IC efficacy between 300 and 600 mg
twice daily, if any, should be investigated in future studies.
3.3 Ceritinib
Ceritinib (LDK378), a highly selective, orally available ALK
inhibitor, has been shown to inhibit ALKwith 20-fold potency
to that of crizotinib and is effective for ALK with several
mutations that confer resistance to crizotinib in preclinical
experiments [54]. In humans, a phase I study investigating
ceritinib demonstrated ORR in pts with or without prior cri-
zotinib treatment of 56 and of 58 %, respectively [9], and
crizotinib followed by ceritinib has been shown to prolong
combined PFS [55]. With regard to the efficacy of ceritinib
for IC metastasis, a preclinical rat model showed that ceritinib
penetrates the BBB with a brain-to-blood exposure ratio of
approximately 15 % [56], and the IC efficacy of ceritinib has
been observed in pts previously treated with or without crizo-
tinib [9].
More detailed data on the efficacy of ceritinib for CNS
metastasis were reported in the ASCEND studies. The
ASCEND-1 study included 124 (50.4 %) pts with baseline
BM among 246 enrolled pts, and 98 of the pts with BM had
been treated with other ALK inhibitors agents. The IC RR and
DCR in the pts with measurable BM were 34.5 % (95 % CI
17.9–54.3) and 58.6 % (95 % CI 38.9–76.5), respectively [17].
Prior ALKi treatment affected the RR and IC DCR: the RR and
IC DCR values in the pts with or without prior ALKi treat-
ment were 29.2 and 60.0 %, and 58.3 and 60.0 %, respectively.
The IC median PFS was reported to be 8.3 and 7.0 months
and not estimable in all pts, the pts with prior ALKi and the
ALKi-naïve pts. The ASCEND-2 trial is a phase II study of
ceritinib in pts with ALK+ NSCLC previously treated with
chemotherapy and crizotinib, and all pts had a history of crizo-
tinib treatment as the last prior systemic anticancer therapy
[18]. One hundred pts (71.4 %) had a history of prior radio-
therapy for BM, and the IC RR and DCR in 33 pts with target
lesions in the brain were 39.4 % (95 % CI 22.9–57.9) and
84.8 % (95 % CI 68.1–94.9), respectively. In addition, the
ASCEND-3 study aimed to investigate the antitumor efficacy
and safety of ceritinib in ALKi-naïve pts with ALK rearrange-
ment who had progressed on one to three lines of chemother-
apy [16]. Among 50 (40.3 %) pts with BM at baseline, 27 pts
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(54.0 %) had been treated with prior radiotherapy to the brain.
The IC RR and DCR in 17 pts with target lesions in the brain
were 58.9 % (95 % CI 32.9–81.6) and 82.4 % (95 % CI 56.6–
96.2), respectively. These findings demonstrate that ceritinib
is highly effective for pts with BM, and intriguingly, the anti-
neoplastic effect of ceritinib against BM is high for pts without
a history of ALKi treatment compared with those pre-treated
with other ALK inhibitors.
3.4 Other ALK inhibitors
Other ALK inhibitors, such as AP26133 and PF-06463922,
have been also shown to be effective for IC metastasis [21,
28]. The phase I/II study of AP26113 included 137 pts with
advanced malignancies, including 79 pts with ALK-
rearranged NSCLC, of whom 52 (66 %) of 79 ALK+ NSCLC
pts had BM at baseline [21]. The IC ORR and DCR in the
ALK+ pts with measurable BM were as high as 53 and 87 %,
respectively. With regard to PF-06463922, the IC RR and
DCR were 36 and 72 %, respectively [28], and the high IC
efficacy of the agent was confirmed in preclinical IC models
[57]. Furthermore, IC data for other novel ALK inhibitors,
such as X-396, TSR-11, and so on, are anticipated to be re-
ported in the near future [58, 59].
4 Beyond PD use of ALKi for BM
In clinical settings using molecular-targeted agents, physi-
cians usually experience cases of PD only in the CNS [60].
Several retrospective studies have demonstrated that the use
of crizotinib beyond progressive disease (CBPD) combined
with cranial radiotherapy for CNS PD might offer a survival
benefit [31, 61, 62]. Takeda and colleagues retrospectively
investigated seven pts with ALK rearrangement who
progressed on crizotinib in isolated CNS lesions and resumed
crizotinib after local ablative therapy (LAT), including stereo-
tactic radiotherapy (SRT) for three pts and WBI for four pts
[60]. The median PFS from the first initiation of crizotinib
was 5.5 months, and all pts were able to continue the treat-
ment with crizotinib for at least 4 months after LAT without
disease progression, suggesting that the addition of LAT to
crizotinib for isolated BM might prolong the total PFS. In
addition to this study, Weickhardt et al. examined LAT for
oligo-progressive disease, including brain and extra-CNS le-
sions, in 25 pts with EGFR-mutated or ALK-rearranged
NSCLC who progressed on erlotinib or crizotinib and were
judged to be suitable for LAT [31]. The PFS achieved with
erlotinib and crizotinib was 13.8 and 9.0 months, respective-
ly, and LAT for CNS, which was a site of first progression,
prolonged the PFS for more than 7.0 months. Although grade
3/4 fatigue was reported in two pts who received WBI, no
other grade 3/4 radiation-related toxicities were observed.
Furthermore, a retrospective investigation of ALK+ pts en-
rolled in the PROFILE 1001 or PROFILE 1005 trials who
were able to continue CBPD demonstrated that CBPD might
be associated with prolonged survival: the OS from the time
of PD in the pts with or without CBPD was 16.4 versus
2.9 months, respectively (hazard ratio (HR) 0.27, 95 % CI
0.17–0.42; P<0.0001) [61]. In addition, the OS from the first
dose of crizotinib in the pts with or without CBPD was 29.6
and 10.8 months, respectively (HR 0.30, 95 % CI 0.19–0.46;
P<0.0001). It should be noted that 51 % of the pts with
CBPD had the brain as a site of PD, while the pts without
CBPD had both the liver (37 %) and the brain (28 %) as PD
sites, suggesting that pts with progressive disease in the CNS
might benefit significantly from CBPD.
Therefore, CBPD for CNS PD appears to prolong survival.
Hence, should physicians always consider CBPD in pts who
relapse on crizotinib in isolated CNS lesions? If we have a
choice to use next-generation ALKi, such as alectinib, after
failure of or intolerance to crizotinib, the answer seems to be
no. As described above, next-generation ALK inhibitors, spe-
cifically alectinib, are highly effective for CNS lesions pre-
treated with crizotinib. In addition to this point, considering
the possible long survival achieved with two or more ALK
inhibitors and cytotoxic chemotherapy and the potential for
late complications of radiotherapy, such as radiation necrosis
and encephalopathy, even isolated CNS metastases should be
considered truly progressive and crizotinib should be changed
to another ALKi. However, if all available ALK inhibitors are
completed, ALKi beyond PD combined with LAT for BM
should be considered, because cytotoxic chemotherapy is usu-
ally ineffective for such lesions. Since these strategies are not
based on definitive data, future studies are warranted to inves-
tigate which strategy, using ALKi beyond PD concurrently
with LAT for BM or switching to other ALK inhibitors or
cytotoxic chemotherapy, is better in terms of the survival ben-
efit and safety.
5 Conclusion
We herein described the detailed data on the frequency of BM
and efficacy of various ALK inhibitors for BM. Although the
brain is thought to be one of the most invulnerable sites, recent
trials have demonstrated that novel ALK inhibitors exhibit
high antineoplastic effects on CNS lesions. Future studies
are warranted to elucidate the most optimal management of
BM in pts with ALK-rearranged NSCLC.
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